Investigation and a pending class action lawsuit against Biovail Corporation, Teva Pharmaceuticals and Elan Corporation on behalf of purchasers of generic Adalat cc 30 mg and 60 mg, generic versions of the blood pressure medicine Adalat CC.
Defendants Biovail Corporation in conjunction with its partner, Teva Pharmaceuticals USA, Inc. and Elan Corporation, plc had been developing rival versions of generic Adalat CC 30 mg and 60 mg.
However, the class action lawsuit alleges that Biovail, Teva and Elan, conspired to ensure that only one version of each drug the 30 mg dosage Adalat and the 60 mg Adalat reached the market. The resulting lack of competition forced purchasers to pay higher prices for the generic drug.
Do not change medications without first consulting your doctor.
The information provided on ClassAdvocate.com is general in nature,
does not apply to any particular factual situation, and is not and
should not be taken as legal or other professional advice. We make no
commitment or warranty that the factual, legal or any other information
on ClassAdvocate.com, or on any linked website, is accurate, complete,
error-free, or current. As such, you should not rely on such information,
and should seek professional advice if and as you determine appropriate.
ClassAdvocate.com is not a lawyer referral service, and no attorney-client
or confidential relationship is or should be formed by use of the site.
The investigations listed on ClassAdvocate.com are attorney advertisements
and do not in any way constitute a referral or endorsement by ClassAdvocate.com
or any approved or authorized lawyer referral service.